Publications list for Associate Professor Georgina Long

2014 | 2013 | 2012 | 2011


  • Menzies, A., Lum, T., Wilmott, J., Hyman, J., Kefford, R., Thompson, J., O'Toole, S., Long, G., Scolyer, R. (2014), Intrapatient Homogeneity of BRAFV600E Expression in Melanoma. The American Journal of Surgical Pathology. 38(3), 377-382. [Abstract]
  • Shi, H., Hong, A., Kong, X., Koya, R., Song, C., Moriceau, G., Hugo, W., Yu, C., Ng, C., Chodon, T., Scolyer, R., Kefford, R., Ribas, A., Long, G., Lo, R. (2014), A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition. Cancer Discovery. 4(1), 69-79. [Abstract]
  • Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R., Moriceau, G., Chodon, T., Guo, R., Johnson, D., Dahlman, K., Kelley, M., Kefford, R., Chmielowski, B., Glaspy, J., Sosman, J., van Baren, N., Long, G., Ribas, A., Lo, R. (2014), Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy. Cancer Discovery. 4(1), 80-93. [Abstract]


  • Kim, K., Kefford, R., Pavlick, A., Infante, J., Ribas, A., Sosman, J., Fecher, L., Millward, M., McArthur, G., Hwu, P., Gonzalez, R., Ott, P., Long, G., Gardner, O., Ouellet, D., Xu, Y., Demarini, D., Le, N., Patel, K., Lewis, K. (2013), Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor. Journal of Clinical Oncology. 31(4), 482-489. [Abstract]
  • Klein, O., Clements, A., Menzies, A., O'Toole, S., Kefford, R., Long, G. (2013), BRAF inhibitor activity in V600R metastatic melanoma. European Journal of Cancer. 49(5), 1073-1079. [Abstract]
  • Long, G., Wilmott, J., Capper, D., Preusser, M., Zhang, Y., Thompson, J., Kefford, R., von Deimling, A., Scolyer, R. (2013), Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma. American Journal of Surgical Pathology. 37(1), 61-65. [Abstract]
  • Carlino, M., Saunders, C., Haydu, L., Menzies, A., Martin Curtis, C., Lebowitz, P., Kefford, R., Long, G. (2013), (18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma. European Journal of Cancer. 49(2), 395-402. [Abstract]
  • Menzies, A., Long, G. (2013), New combinations and immunotherapies for melanoma: latest evidence and clinical utility. Therapeutic Advances in Medical Oncology. 5(5), 278-285. [Abstract]
  • Lyle, M., Long, G. (2013), Diagnosis and Treatment of KIT-Mutant Metastatic Melanoma. Journal of Clinical Oncology. 31(26), 3176-3181. [Abstract]
  • Nathanson, K., Martin, A., Wubbenhorst, B., Greshock, J., Letrero, R., D'Andrea, K., O'Day, S., Infante, J., Falchook, G., Arkenau, H., Millward, M., Brown, M., Pavlick, A., Davies, M., Ma, B., Gagnon, R., Curtis, M., Lebowitz, P., Kefford, R., Long, G. (2013), Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436). Clinical Cancer Research. 19(17), 4868-4878. [Abstract]
  • Ascierto, P., Minor, D., Ribas, A., Lebbe, C., O'Hagan, A., Arya, N., Guckert, M., Schadendorf, D., Kefford, R., Grob, J., Hamid, O., Amaravadi, R., Simeone, E., Wilhelm, T., Kim, K., Long, G., Martin, A., Mazumdar, J., Goodman, V., Trefzer, U. (2013), Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma. Journal of Clinical Oncology. 31(26), 3205-3211. [Abstract]
  • Anforth, R., Blumetti, T., Clements, A., Kefford, R., Long, G., Fernandez-Penas, P. (2013), Systemic Retinoids for the Chemoprevention of Cutaneous Squamous Cell Carcinoma and Verrucal Keratosis in a Cohort of Patients on BRAF inhibitors. The British Journal of Dermatology. 169(6), 1310-1313. [Abstract]
  • Menzies, A., Long, G. (2013), Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. European Journal of Cancer. 49(15), 3229-3241. [Abstract]
  • Menzies, A., Kefford, R., Long, G. (2013), Paradoxical oncogenesis: are all BRAF inhibitors equal?. Pigment Cell & Melanoma Research. 26(5), 611-615. [Abstract]
  • Carlino, M., Gowrishankar, K., Saunders, C., Pupo, G., Snoyman, S., Zhang, X., Saw, R., Becker, T., Kefford, R., Long, G., Rizos, H. (2013), Anti-proliferative effects of continued mitogen activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma. Molecular Cancer Therapeutics. 12(7), 1332-1342. [Abstract]
  • Trunzer, K., Pavlick, A., Schuchter, L., Gonzalez, R., McArthur, G., Hutson, T., Moschos, S., Flaherty, K., Kim, K., Weber, J., Hersey, P., Long, G., Lawrence, D., Ott, P., Amaravadi, R., Lewis, K., Puzanov, I., Lo, R., Koehler, A., Kockx, M., Spleiss, O., Schell-Steven, A., Gilbert, H., Cockey, L., Bollag, G., Lee, R., Joe, A., Sosman, J., Ribas, A. (2013), Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. Journal of Clinical Oncology. 31(14), 1767-1774. [Abstract]
  • Long, G., Wilmott, J., Haydu, L., Tembe, V., Sharma, R., Rizos, H., Thompson, J., Howle, J., Scolyer, R., Kefford, R. (2013), Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment and on progression. Pigment Cell and Melanoma Research. 26(4), 499-508. [Abstract]
  • Klein, O., Ribas, A., Chmielowski, B., Walker, G., Clements, A., Long, G., Kefford, R. (2013), Facial Palsy As a Side Effect of Vemurafenib Treatment in Patients With Metastatic Melanoma. Journal of Clinical Oncology. 31(12), e215-217. [Abstract]
  • Klein, O., Clements, A., Menzies, A., O'Toole, S., Kefford, R., Long, G. (2013), BRAF inhibitor activity in V600R metastatic melanoma - Response. European Journal of Cancer. , 1797-1798. [Abstract]
  • Wilmott, J., Menzies, A., Haydu, L., Capper, D., Preusser, M., Zhang, Y., Thompson, J., Kefford, R., von Deimling, A., Scolyer, R., Long, G. (2013), BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma. British Journal of Cancer. 108(4), 924-931. [Abstract]
  • Anforth, R., Fernandez-Peñas, P., Long, G. (2013), Cutaneous toxicities of RAF inhibitors. The Lancet Oncology. 14(1), e11-18. [Abstract]
  • Hu, W., Jin, L., Jiang, C., Long, G., Scolyer, R., Wu, Q., Zhang, X., Mei, Y., Wu, M. (2013), AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma. Cell Death & Disease. 4, e914. [Abstract]
  • Long, G., Margolin, K. (2013), Multidisciplinary approach to brain metastasis from melanoma. American Society of Clinical Oncology Educational Book. 2013, 393-398. [Abstract]


  • Flaherty, K., Infante, J., Daud, A., Gonzalez, R., Kefford, R., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., Kudchadkar, R., Burris, H., Falchook, G., Algazi, A., Lewis, K., Long, G., Puzanov, I., Lebowitz, P., Singh, A., Little, S., Sun, P., Allred, A., Ouellet, D., Kim, K., Patel, K., Weber, J. (2012), Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. The New England journal of medicine. 367(18), 1694-1703. [Abstract]
  • Long, G., Trefzer, U., Davies, M., Kefford, R., Ascierto, P., Chapman, P., Puzanov, I., Hauschild, A., Robert, C., Algazi, A., Mortier, L., Tawbi, H., Wilhelm, T., Zimmer, L., Switzky, J., Swann, S., Martin, A., Guckert, M., Goodman, V., Streit, M., Kirkwood, J., Schadendorf, D. (2012), Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. The Lancet Oncology. 13(11), 1087-1095. [Abstract]
  • Wilmott, J., Tembe, V., Howle, J., Sharma, R., Thompson, J., Rizos, H., Lo, R., Kefford, R., Scolyer, R., Long, G. (2012), Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine. Molecular Cancer Therapeutics. 11(12), 2704-2708. [Abstract]
  • Wilmott, J., Scolyer, R., Long, G., Hersey, P. (2012), Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. Oncoimmunology. 1(6), 997-999. [Abstract]
  • Anforth, R., Blumetti, T., Kefford, R., Sharma, R., Scolyer, R., Kossard, S., Long, G., Fernandez-Pe��as, P. (2012), Cutaneous Manifestations of Dabrafenib (GSK2118436): A Selective Inhibitor of Mutant BRAF in patients with Metastatic Melanoma. British Journal of Dermatology. 167(5), 1153-1160. [Abstract]
  • Zimmer, L., Hillen, U., Livingstone, E., Lacouture, M., Busam, K., Carvajal, R., Egberts, F., Hauschild, A., Kashani-Sabet, M., Goldinger, S., Dummer, R., Long, G., McArthur, G., Scherag, A., Sucker, A., Schadendorf, D. (2012), Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition. Journal of Clinical Oncology. 30(19), 2375-2383. [Abstract]
  • Murali, R., Brown, P., Kefford, R., Scolyer, R., Thompson, J., Atkins, M., Long, G. (2012), Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma. Cancer. 118(18), 4519-4529. [Abstract]
  • Menzies, A., Haydu, L., Visintin, L., Carlino, M., Howle, J., Thompson, J., Kefford, R., Scolyer, R., Long, G. (2012), Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma. Clinical Cancer Research. 18(12), 3242-3249. [Abstract]
  • Murali, R., Haydu, L., Long, G., Quinn, M., Saw, R., Shannon, K., Spillane, A., Stretch, J., Kefford, R., Thompson, J., Scolyer, R. (2012), Clinical and Pathologic Factors Associated with Distant Metastasis and Survival in Patients with Thin Primary Cutaneous Melanoma. Annals of Surgical Oncology. 19(6), 1782-1789. [Abstract]
  • Falchook, G., Long, G., Kurzrock, R., Kim, K., Arkenau, T., Brown, M., Hamid, O., Infante, J., Millward, M., Pavlick, A., O'Day, S., Blackman, S., Curtis, C., Lebowitz, P., Ma, B., Ouellet, D., Kefford, R. (2012), Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. The Lancet. 379(9829), 1893-1901. [Abstract]
  • Shi, H., Moriceau, G., Kong, X., Koya, R., Nazarian, R., Pupo, G., Bacchiocchi, A., Dahlman, K., Chmielowski, B., Sosman, J., Halaban, R., Kefford, R., Long, G., Ribas, A., Lo, R. (2012), Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors. Cancer Discovery. 2(5), 414-424. [Abstract]
  • Wilmott, J., Long, G., Howle, J., Haydu, L., Sharma, R., Thompson, J., Kefford, R., Hersey, P., Scolyer, R. (2012), Selective BRAF inhibitors induce marked T cell infiltration into human metastatic melanoma. Clinical Cancer Research. 18(5), 1386-1394. [Abstract]
  • Shi, H., Moriceau, G., Kong, X., Lee, M., Lee, H., Koya, R., Ng, C., Chodon, T., Scolyer, R., Dahlman, K., Sosman, J., Kefford, R., Long, G., Nelson, S., Ribas, A., Lo, R. (2012), Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nature Communications. 3(2), 724. [Abstract]
  • Menzies, A., Long, G., Murali, R. (2012), Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Design, Development and Therapy. 6, 391-405. [Abstract]
  • Carlino, M., Fogarty, G., Long, G. (2012), Treatment of melanoma brain metastases: a new paradigm. Cancer Journal. 18(2), 208-212. [Abstract]


  • Long, G., Menzies, A., Nagrial, A., Haydu, L., Hamilton, A., Mann, G., Hughes, T., Thompson, J., Scolyer, R., Kefford, R. (2011), Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma. Journal of Clinical Oncology. 29(10), 1239-1246. [Abstract]
  • Scolyer, R., Long, G., Thompson, J. (2011), Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. Molecular oncology. 5(2), 124-36. [Abstract]
  • Arkenau, H., Kefford, R., Long, G. (2011), Targeting BRAF for patients with melanoma. British journal of cancer. 104(3), 392-8. [Abstract]